Trending: Halozyme Drops Bid for Evotec

Dow Jones

2024-11-23

1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme Therapeutics said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Dow Jones & Co. owns Factiva. (matthew.walker@dowjones.com)

(END) Dow Jones Newswires

November 22, 2024 13:50 ET (18:50 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2485909142"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485909142\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2485909142?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-23 02:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485909142","market":"other","top_or_hot":-1,"title":"Trending: Halozyme Drops Bid for Evotec","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Dow Jones &amp; Co. owns Factiva. (matthew.walker@dowjones.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 22, 2024 13:50 ET (18:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trending: Halozyme Drops Bid for Evotec</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrending: Halozyme Drops Bid for Evotec\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-23 02:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Dow Jones &amp; Co. owns Factiva. (matthew.walker@dowjones.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 22, 2024 13:50 ET (18:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2485909142","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485909142","pubTimestamp":1732301400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme Therapeutics said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros . Dow Jones & Co. owns Factiva. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HALO":"奥洛兹美医疗","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"趋势：Halozyme放弃对Evotec的收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":0.9},"content_text":"1350 ET -- German drug developer Evotec is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Halozyme Therapeutics said it was ending an effort to acquire Evotec. Halozyme Chief Executive Helen Torley said Friday that Evotec has been unwilling to engage on a potential deal, leading the biopharmaceutical company to withdraw its proposal. San Diego-based Halozyme last week made a non-binding proposal to acquire Evotec for 11 euros a share in cash that put the deal's valuation around 2 billion euros ($2.09 billion). Dow Jones & Co. owns Factiva. (matthew.walker@dowjones.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 22, 2024 13:50 ET (18:50 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}